Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Bone. 2016 Apr 30;88:138–145. doi: 10.1016/j.bone.2016.04.028

Fig. 2.

Fig. 2

Bone mineral content (BMC) was measured by DEXA at the end of the experiment (21 wks of age) using an ROI that encompassed (A) the whole body, (B) the lumbar spine (L3–L5, inclusive), and (C) the hindlimb (all skeletal tissue distal to the acetabulum). Tamoxifen reduced BMC in Cre-positive mice but not in Cre negative mice (* p < 0.05 compared to CreERt2− with Oil group, + p < 0.05 compared to CreERt2− with tamoxifen group, # p < 0.05 compared to CreERt2+ with Oil group). (D–F) Bone mineral density (BMD) was also obtained from the same DEXA scans, and yielded similar reductions in skeletal properties among the βcat–recombined mice. Sample size is n=10/group.